- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04396821
Испытание по оценке безопасности и переносимости TST001 при запущенных или метастатических солидных опухолях
Клинические испытания фазы I/IIa для оценки безопасности, переносимости и фармакокинетики TST001, вводимого в качестве монотерапии или в комбинации с ниволумабом у пациентов с местнораспространенными или метастатическими солидными опухолями
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers.
Обзор исследования
Статус
Подробное описание
Part A of the trial will consist of two cohorts, one dosed every 2 weeks and one dosed every 3 weeks in a standard 3+3 design. Part A is the dose finding portion of the trial.
18 to 36 participants will be enrolled.
Part B consists of 3 cohorts:
Cohort A is for patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma. Patients will receive TST001 at 2mg/kg or 4mg/kg Q2W plus Nivolumab and mFOLFOX6. Alternative allocation of patients between the 2 doses will be performed. The first 6 patients at each dose level as the lead-in phase will not be selected on the basis of their tumor's CLDN18.2 expression. Approximately 12-42 patients will be enrolled in Cohort A.
Cohort B is for patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies. Patient will receive TST001 plus Nivolumab. No selection based on CLDN18.2 expression will be required for the safety run-in (3-6 patients). Patients with CLDN18.2 expression in tumor tissue tested by the central laboratory will be enrolled in the expansion phase. Safety run-in phase will follow 3+3 rule with two dose levels, TST001 3mg/kg and 6mg/kg Q3W combined with nivolumab. Approximately 30 patients will be enrolled in Cohort B including the patients in the safety run-in phase.
Cohort C is for patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma; Patients will receive TST001 at 2mg/kg or 4mg/kg Q2W plus gemcitabine and albumin-bound paclitaxel. Alternative allocation of patients between the 2 doses will be performed. The first 6 patients at each dose level as the lead-in phase will not be selected on the basis of their tumor's CLDN18.2 expression. Approximately 12-42 patients will be enrolled in Cohort C.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
Arizona
-
Gilbert, Arizona, Соединенные Штаты, 85234
- Banner MD Anderson
-
Tucson, Arizona, Соединенные Штаты, 85724
- University of Arizona
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06519
- Yale University
-
-
Florida
-
Sarasota, Florida, Соединенные Штаты, 34232
- Florida Cancer Specialists
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30033
- Emory University
-
-
Kansas
-
Kansas City, Kansas, Соединенные Штаты, 66160
- University of Kansas, School of Medicine
-
-
Missouri
-
St Louis, Missouri, Соединенные Штаты, 63110
- Washington University
-
-
New York
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering
-
Stony Brook, New York, Соединенные Штаты, 11794
- Stony Brook Cancer Center
-
-
North Carolina
-
Winston-Salem, North Carolina, Соединенные Штаты, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Canton, Ohio, Соединенные Штаты, 44718
- Gabrail Cancer Research
-
-
Pennsylvania
-
Gettysburg, Pennsylvania, Соединенные Штаты, 17325
- Pennsylvania Cancer Specialist Research Institute
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15212
- Allegheny Hospital
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Соединенные Штаты, 37232
- Vanderbilt University
-
-
Texas
-
Austin, Texas, Соединенные Штаты, 78704
- NEXT Oncology
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98104
- Swedish Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, Соединенные Штаты, 53226
- Medical College of Wisconsin
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Male or female ≥ 18 years.
- Patients with histologically or cytologically confirmed, locally advanced or metastatic solid tumors.
Part A only:
* Patients must be: a) progressed after standard therapies, b) intolerant of standard therapies, or c) with a tumor type without standard therapy.
Part B only:
- Cohort A: Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma; prior adjuvant or neoadjuvant therapy are allowed only if disease progressed or recurred at least 6 months after completion of these treatments. Patients may have received one infusion of mFOLFOX6 plus nivolumab during the screening period.
- Cohort B: Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies; adjuvant or neoadjuvant therapy could be regarded as one line of therapy only if disease progressed or recurred during these treatments or within 6 months or less after completion of these treatments.
- Cohort C: Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma; prior adjuvant or neoadjuvant therapy are allowed only if disease progressed or recurred at least 6 months after completion of these treatments. Patients may have received up to 2 infusions of Gemcitabine + albumin-bound paclitaxel (with one week between each infusion) during the screening period.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS): 0-1 .
- Patients with adequate cardiac, liver, renal function, etc.
Exclusion Criteria
- Symptomatic central nervous system metastases.
- Prior treatment with any CLDN18.2 target agents
- Allergy or sensitivity to TST001 or known allergies to comparable drugs
- Documented history of multiple other allergies requiring interventions
- Severe cardiovascular disease, including CVA, TIA, myocardial infarction, or unstable angina, NYHA class III or IV heart failure or uncontrolled arrhythmia within 6 months of study entry, severe QTc prolongation, concomitant risks for QTc prolongation.
- Concurrent malignancy within 5 years prior to entry except adequately treated certain types of cancer
- Active and clinically significant infections, known uncontrolled infections with hepatitis B, hepatitis C, known human immunodeficiency virus with acquired immunodeficiency syndrome related illness
- Any condition that the investigator or primary physician believes may not be appropriate for participating in the study.
Other protocol-defined Inclusion/Exclusion Criteria could apply.
.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Part A Q2W
Dosed every 2 weeks IV with TST001, starting dose is 1 mg/kg, multiple dose levels will be tested. |
TST001 is a humanized IgG1 monoclonal antibody. |
|
Экспериментальный: Part A Q3W
Dosed every 3 weeks IV with TST001, starting dose is 3 mg/kg, and multiple dose levels will be tested. |
TST001 is a humanized IgG1 monoclonal antibody. |
|
Экспериментальный: Part B Cohort A
Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma. |
TST001 is a humanized IgG1 monoclonal antibody. Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin. |
|
Экспериментальный: Part B Cohort B
Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies. |
TST001 is a humanized IgG1 monoclonal antibody. Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies |
|
Экспериментальный: Part B Cohort C
Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma. |
TST001 is a humanized IgG1 monoclonal antibody. Chemotherapy medication
Другие имена:
Chemotherapy medication |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Participant Safety as characterized by frequency and severity of adverse events
Временное ограничение: up to 100 days following last dose
|
Characterization of TST001 safety profile including frequency and severity of adverse events that are related to treatment. |
up to 100 days following last dose
|
|
Maximum Tolerated Dose (MTD or Recommended Phase 2 Dose (RP2D)
Временное ограничение: up to 100 days following last dose
|
As measured by number of participants experiencing dose related toxicity (DLT) in each escalating cohort |
up to 100 days following last dose
|
|
Participant Safety and Tolerability of TST001 in combination with Nivolumab as characterized by frequency and severity of adverse events
Временное ограничение: Up to 100 days following last dose
|
Characterization of TST001 + Nivolumab safety profile including frequency and severity of adverse events that are related to treatment. |
Up to 100 days following last dose
|
|
Participant Safety and Tolerability of TST001 in combination with Nivolumab and mFOLFOX6 as characterized by frequency and severity of adverse events
Временное ограничение: Up to 100 days following last dose
|
Characterization of TST001 + Nivolumab + mFOLFOX6 safety profile including frequency and severity of adverse events that are related to treatment. |
Up to 100 days following last dose
|
|
Participant Safety and Tolerability of TST001 in combination with gemcitabine and albumin-bound paclitaxel as characterized by frequency and severity of adverse events
Временное ограничение: Up to 100 days following last dose
|
Characterization of TST001 + Gemcitabine + albumin-bound paclitaxel safety profile including frequency and severity of adverse events that are related to treatment. |
Up to 100 days following last dose
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Immunogenicity
Временное ограничение: up to 30 days following last dose
|
by measurement of Incidence of anti-drug antibodies (ADA) |
up to 30 days following last dose
|
|
Objective response rate (ORR)
Временное ограничение: up to 24 months, until disease progression or start of another anti-cancer therapy
|
as measured by RECIST 1.1 |
up to 24 months, until disease progression or start of another anti-cancer therapy
|
|
Duration of Response (DOR)
Временное ограничение: up to 24 months, until disease progression or start of another anti-cancer therapy
|
duration of response (DOR) |
up to 24 months, until disease progression or start of another anti-cancer therapy
|
|
Progression free survival (PFS)
Временное ограничение: up to 24 months, until disease progression or start of another anti-cancer therapy
|
as measured by RECIST v1.1 |
up to 24 months, until disease progression or start of another anti-cancer therapy
|
|
PK parameters
Временное ограничение: Up to 30 days following last dose
|
Maximum serum concentration (Cmax) |
Up to 30 days following last dose
|
|
PK
Временное ограничение: Up to 30 days following last dose
|
time to reach maximum serum concentration (Tmax) |
Up to 30 days following last dose
|
|
PK
Временное ограничение: Up to 30 days following last dose
|
Area Under the Curve |
Up to 30 days following last dose
|
Соавторы и исследователи
Соавторы
Следователи
- Директор по исследованиям: Charlie Qi, MD, Suzhou Transcenta Therapeutics Co.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания эндокринной системы
- Новообразования по локализации
- Новообразования
- Желудочно-кишечные новообразования
- Новообразования пищеварительной системы
- Заболевания пищеварительной системы
- Желудочно-кишечные заболевания
- Заболевания желудка
- Новообразования эндокринных желез
- Заболевания поджелудочной железы
- Новообразования желудка
- Новообразования поджелудочной железы
- Аминокислоты, пептиды и белки
- Белки
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Углеводороды
- Циклопарафины
- Углеводороды, алициклический
- Углеводороды, циклические
- Терпена
- Антитела, моноклональные, гуманизированные
- Антитела, моноклональные
- Антитела
- Иммуноглобулины
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Таксииды
- Циклодеканы
- Diterpenes
- Дезоксицитидин
- Цитидин
- Пиримидиновые нуклеозиды
- Пиримидины
- Альбумины
- Паклитаксел
- Ниволумаб
- Связанный с альбумином паклитаксел
- Гемцитабин
Другие идентификационные номера исследования
- TST001-1001
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
As described below. Patient personal data will be kept confidential as per HIPAA.
Сроки обмена IPD
Clinical Study Report will become available approximately 60 to 90 days after last patient last visit. Each Investigator will receive one to keep. Protocol will be received prior to study start for each investigator.
Критерии совместного доступа к IPD
Be an active investigator in the TST001-1001 trial
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- КСО
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .